These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1492 related articles for article (PubMed ID: 33191206)
1. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action. Yousefi H; Mashouri L; Okpechi SC; Alahari N; Alahari SK Biochem Pharmacol; 2021 Jan; 183():114296. PubMed ID: 33191206 [TBL] [Abstract][Full Text] [Related]
2. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. Simonis A; Theobald SJ; Fätkenheuer G; Rybniker J; Malin JJ EMBO Mol Med; 2021 Jan; 13(1):e13105. PubMed ID: 33015938 [TBL] [Abstract][Full Text] [Related]
3. [The medicinal treatment of COVID-19: a brief update]. de Boer MGJ; Gieling EM; van der Linden PD; Sinha BNM; Vollaard AM Ned Tijdschr Geneeskd; 2020 Nov; 164():. PubMed ID: 33331727 [TBL] [Abstract][Full Text] [Related]
4. Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century. Sanghai N; Shafiq K; Tranmer GK Mini Rev Med Chem; 2021; 21(1):3-9. PubMed ID: 32838716 [TBL] [Abstract][Full Text] [Related]
5. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2. Andreou A; Trantza S; Filippou D; Sipsas N; Tsiodras S In Vivo; 2020 Jun; 34(3 Suppl):1567-1588. PubMed ID: 32503814 [TBL] [Abstract][Full Text] [Related]
6. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT mBio; 2021 Jan; 12(1):. PubMed ID: 33468703 [TBL] [Abstract][Full Text] [Related]
7. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine. Choudhury M; Dhanabalan AK; Goswami N J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481 [TBL] [Abstract][Full Text] [Related]
8. On the molecular structure of Remdesivir for the treatment of Covid-19. Sheikholeslami SM; Jahanbani A; Shao Z Comput Methods Biomech Biomed Engin; 2021 Jul; 24(9):995-1002. PubMed ID: 33356621 [TBL] [Abstract][Full Text] [Related]
9. Current pharmacological treatments for SARS-COV-2: A narrative review. Nittari G; Pallotta G; Amenta F; Tayebati SK Eur J Pharmacol; 2020 Sep; 882():173328. PubMed ID: 32603692 [TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection. Ye ZW; Yuan S; Chan JF; Zhang AJ; Yu CY; Ong CP; Yang D; Chan CC; Tang K; Cao J; Poon VK; Chan CC; Cai JP; Chu H; Yuen KY; Jin DY Emerg Microbes Infect; 2021 Dec; 10(1):291-304. PubMed ID: 33538646 [TBL] [Abstract][Full Text] [Related]
11. Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells. Sacramento CQ; Fintelman-Rodrigues N; Dias SSG; Temerozo JR; Da Silva APD; da Silva CS; Blanco C; Ferreira AC; Mattos M; Soares VC; Pereira-Dutra F; Miranda MD; Barreto-Vieira DF; da Silva MAN; Santos SS; Torres M; Chaves OA; Rajoli RKR; Paccanaro A; Owen A; Bou-Habib DC; Bozza PT; Souza TML Viruses; 2022 Feb; 14(2):. PubMed ID: 35215969 [TBL] [Abstract][Full Text] [Related]
12. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment. Khazir J; Maqbool T; Mir BA Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800 [TBL] [Abstract][Full Text] [Related]
13. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications. Ballout RA; Sviridov D; Bukrinsky MI; Remaley AT FASEB J; 2020 Jun; 34(6):7253-7264. PubMed ID: 32367579 [TBL] [Abstract][Full Text] [Related]
14. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies. Goel B; Bhardwaj N; Tripathi N; Jain SK Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848 [TBL] [Abstract][Full Text] [Related]
15. COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine. Guan W; Lan W; Zhang J; Zhao S; Ou J; Wu X; Yan Y; Wu J; Zhang Q Virol Sin; 2020 Dec; 35(6):685-698. PubMed ID: 32997322 [TBL] [Abstract][Full Text] [Related]
17. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19. Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457 [TBL] [Abstract][Full Text] [Related]
18. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. Cantini F; Goletti D; Petrone L; Najafi Fard S; Niccoli L; Foti R Drugs; 2020 Dec; 80(18):1929-1946. PubMed ID: 33068263 [TBL] [Abstract][Full Text] [Related]
19. Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance. Moirangthem DS; Surbala L Curr Drug Targets; 2021; 22(12):1346-1356. PubMed ID: 33267759 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment. Jung LS; Gund TM; Narayan M Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]